world-biomarkers-pharma-biotech-2017-tracks

6 / 28

Notes:
Volume10, Issue 12 (Suppl) J Proteomics Bioinform, an open access journal
ISSN: 0974-276X
Page 30
conferenceseries.com
World Biomarkers & Pharma Biotech 2017
December 07-09, 2017
December 07-09, 2017 | Madrid, Spain
&
20th International Conference on
PHARMACEUTICAL BIOTECHNOLOGY
9th WORLD BIOMARKERS CONGRESS
JOINT EVENT ON
The ERK MAP kinase-PEA3/ETV4-MMP-1 axis is operative in oesophageal adenocarcinoma
Yeng S Ang1,2
1Salford Royal University Hospital, UK
2University of Manchester, UK
Many members of the ETS-domain transcription factor family are important drivers of tumorigenesis. Their activation by
Ras-ERK pathway signaling is particularly relevant to the tumorigenic properties of many ETS-domain transcription
factors. The PEA3 subfamily of ETS-domain transcription factors have been implicated in tumor metastasis in several solid
tumors. We have studied the expression of the PEA3 subfamily members PEA3/ETV4 and ER81/ETV1 in oesophageal
adenocarcinomas and determined their role in oesophageal adenocarcinoma cell function. PEA3 plays an important role in
controlling both the proliferation and invasive properties of OE33 oesophageal adenocarcinoma cells and a key target gene
is MMP-1. The ERK MAP kinase pathway activates PEA3 subfamily members and also plays a role in these PEA3 controlled
events, establishing the ERK-PEA3-MMP-1 axis as important in OE33 cells. PEA3 subfamily members are upregulated in
human adenocarcinomas and expression correlates with MMP-1 expression and late stage metastatic disease. Enhanced ERK
signaling is also more prevalent in late stage oesophageal adenocarcinomas. This study shows that the ERK-PEA3-MMP-1
axis is upregulated in oesophageal adenocarcinoma cells and is a potentially important driver of the metastatic progression of
oesophageal adenocarcinomas.
Biography
Yeng S Ang has an international professional standing and research expertise to enhance clinical interventions in Barrett's oesophagus and oesophageal cancer.
He is a Member of the BSG/National Clinical Research Institute Upper GI early cancer prevention research subgroup. He is a peer reviewer for the NIHR RFPB
programme and a member of the Research Steering Board of Manchester Cancer Research Centre (Cancer Research UK Manchester Institute). These research
initiatives have shaped his contribution for the management of GORD, Barrett’s oesophagus and oesophageal cancer. He has published over 45 articles and he is
a Supervisor for PhD and MD students in the molecular cancer group of the University of Manchester.
Yeng S Ang, J Proteomics Bioinform 2017, 10:12(Suppl)
DOI: 10.4172/0974-276X-C1-109